Jatenzo Safety in Older Adults (50 to 64): What the Evidence Shows

Why the 50 to 64 Age Group Needs Special Attention

Men between 50 and 64 occupy a clinical gray zone. Testosterone levels decline at roughly 1 to 2% per year after age 30, and by the sixth decade many men meet the biochemical threshold for hypogonadism 1. At the same time, cardiovascular disease prevalence rises sharply, statin and antihypertensive use becomes common, and the risk-benefit calculus for testosterone replacement therapy (TRT) shifts.

Age-Related Decline and Diagnostic Thresholds

The Baltimore Longitudinal Study of Aging found that approximately 20% of men over 60 and 30% of men over 70 have total testosterone below 325 ng/dL 1. The Endocrine Society's 2018 guideline recommends confirming hypogonadism with two morning total testosterone measurements below 300 ng/dL before initiating therapy 2. For men aged 50 to 64, the guideline explicitly advises weighing cardiovascular comorbidities and discussing the uncertain long-term cardiac safety profile with the patient.

Why Oral TRT Changes the Conversation

Jatenzo was FDA-approved in March 2019 as the first oral testosterone undecanoate for hypogonadism in the United States. Unlike injectable testosterone cypionate or topical gels, Jatenzo is absorbed through the intestinal lymphatic system rather than the portal vein, which reduces first-pass hepatic metabolism 3. This matters for older adults because it offers a route that avoids repeated injections (relevant in men with mobility limitations or needle aversion) and eliminates the transference risk associated with topical formulations.

Key Trial Evidence: The Swerdloff Study

The registration trial for Jatenzo enrolled 166 hypogonadal men across multiple age groups. At 3 months, 87% of patients reached a serum testosterone level within the eugonadal range (300 to 1,100 ng/dL) 3. The study used a dose-titration design starting at 237 mg twice daily, with adjustments to 158 mg or 316 mg based on serum levels.

Efficacy Across Age Subgroups

While the trial was not powered to detect age-specific efficacy differences, subgroup analyses showed consistent testosterone normalization rates across men in their 40s, 50s, and early 60s. The mean age of trial participants was 54 years, placing the bulk of the data squarely within the 50-to-64 window 3.

Tolerability Profile in the Key Cohort

Common adverse events in the trial included headache (5.4%), nausea (4.2%), and diarrhea (3.6%). The discontinuation rate for adverse events was 7.2%, which is comparable to rates seen with injectable testosterone formulations in similar populations 3.

Cardiovascular Safety: The Central Concern

The FDA issued a class-wide label update for testosterone products in 2015, adding a warning about possible increased risk of heart attack and stroke 4. For Jatenzo specifically, the FDA went further: the label carries a boxed warning about blood pressure increases, making it the only testosterone product with this particular warning.

Blood Pressure Elevations

In the key trial, mean systolic blood pressure increased by 3 to 5 mmHg from baseline 3. That number sounds small. For a 55-year-old man already on the cusp of stage 1 hypertension (systolic 130 to 139 mmHg), an additional 3 to 5 mmHg could push readings into a range requiring medication adjustment or new antihypertensive therapy.

The 2017 ACC/AHA blood pressure guideline lowered the hypertension threshold to 130/80 mmHg 5. Under this definition, a substantial proportion of men aged 50 to 64 already meet criteria for hypertension. Starting Jatenzo without baseline blood pressure documentation and a monitoring plan is, in the Endocrine Society's framing, inconsistent with responsible TRT prescribing 2.

The TRAVERSE Trial and Broader Cardiovascular Context

The TRAVERSE trial (N=5,204) published in 2023 provided the most definitive cardiovascular safety data for testosterone therapy to date. It found that transdermal testosterone did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo over a mean follow-up of 33 months (hazard ratio 0.99; 95% CI 0.81 to 1.21) 6. The mean age of participants was 63.3 years, and 35% had pre-existing cardiovascular disease.

TRAVERSE did not study Jatenzo specifically, so its findings cannot be directly extrapolated to the oral formulation. The blood pressure signal unique to Jatenzo's boxed warning remains a distinguishing factor.

Practical Blood Pressure Monitoring Protocol

For men aged 50 to 64 starting Jatenzo, a reasonable monitoring schedule includes baseline blood pressure (ideally as a mean of two readings on separate days), a repeat check at 1 month, then at 3 and 6 months, and every 6 to 12 months thereafter. Home blood pressure monitoring can supplement clinic readings and catch white-coat or masked hypertension patterns. If systolic BP rises above 140 mmHg on two consecutive visits, re-evaluating the need for Jatenzo is appropriate before simply adding antihypertensives.

Hematocrit and Polycythemia Risk

Testosterone stimulates erythropoiesis. All TRT formulations carry a risk of polycythemia (hematocrit ≥54%), which increases blood viscosity and may raise thromboembolic risk 2. In the Jatenzo key trial, polycythemia occurred in approximately 5.8% of participants 3.

Why This Matters More After 50

Baseline hematocrit tends to be higher in older men, partly due to chronic low-grade dehydration and partly because of comorbid conditions like sleep apnea (which independently raises red blood cell production). A man who starts Jatenzo with a baseline hematocrit of 48% has a narrower margin before reaching the 54% threshold than a 30-year-old starting at 44%.

When to Hold or Stop

The Endocrine Society recommends checking hematocrit at baseline, at 3 to 6 months, and then annually 2. If hematocrit exceeds 54%, the guideline recommends dose reduction or temporary cessation. Therapeutic phlebotomy is sometimes used as a bridge, though it does not address the underlying erythropoietic drive. For men aged 50 to 64 with obstructive sleep apnea, screening and treating the sleep disorder before (or concurrent with) starting Jatenzo can help reduce the additive hematocrit risk.

Liver Safety: What the Lymphatic Absorption Route Means

Older oral androgens, particularly 17-alpha-alkylated compounds like methyltestosterone, carried significant hepatotoxicity risk including peliosis hepatis and cholestatic jaundice 7. Jatenzo is not 17-alpha-alkylated. Its testosterone undecanoate formulation is absorbed via intestinal lymphatic pathways, largely bypassing hepatic first-pass metabolism 3.

Clinical Liver Monitoring

In the key trial, clinically significant transaminase elevations (ALT or AST greater than 3 times the upper limit of normal) were rare 3. Routine liver function testing is not mandated by the Jatenzo label, but many clinicians obtain baseline hepatic panels in men over 50 because of the high background prevalence of nonalcoholic fatty liver disease (NAFLD) in this demographic. A baseline value also helps distinguish a Jatenzo-related elevation from a pre-existing condition if liver enzymes rise during follow-up.

Polypharmacy Considerations in the 50 to 64 Age Group

The average American aged 55 to 64 takes four prescription medications 8. When Jatenzo enters that mix, several drug interactions become relevant.

Anticoagulants

Testosterone can increase the effect of warfarin and other vitamin K antagonists by altering clotting factor synthesis. The Jatenzo label recommends more frequent INR monitoring when co-administered with warfarin 9. Direct oral anticoagulants (DOACs) like apixaban or rivarelbaan do not have the same pharmacodynamic interaction, but the polycythemia-driven increase in blood viscosity is an additive thrombotic concern regardless of anticoagulant type.

Insulin and Oral Hypoglycemics

Testosterone may improve insulin sensitivity, and case reports describe hypoglycemia in men with type 2 diabetes who begin TRT without adjusting their diabetes medications 2. For men aged 50 to 64 on metformin, sulfonylureas, or insulin, blood glucose should be monitored more frequently in the first 1 to 3 months after starting Jatenzo.

Corticosteroids

Concurrent corticosteroid use (common in men with inflammatory conditions, COPD, or autoimmune disease) can compound fluid retention, edema, and blood pressure effects. If a patient takes chronic prednisone alongside Jatenzo, blood pressure and weight should be tracked at every visit.

Statin Co-Prescribing

No direct pharmacokinetic interaction between Jatenzo and statins has been identified. The clinical relevance is indirect: testosterone therapy can raise LDL cholesterol modestly in some men, and the Endocrine Society advises monitoring lipid panels at 6 to 12 months after starting TRT 2. For a man already on atorvastatin, this may mean confirming that his current statin dose still achieves target LDL.

Prostate Safety Monitoring

The relationship between testosterone and prostate cancer has been debated for decades. Current evidence does not support the historical assumption that TRT causes prostate cancer, but the Endocrine Society recommends against initiating testosterone in men with untreated, locally advanced, or metastatic prostate cancer 2.

PSA Screening Before and During Therapy

For men aged 50 to 64, the guideline recommends a baseline PSA and digital rectal exam before starting TRT, with repeat PSA at 3 to 6 months, 12 months, and then annually 2. A PSA increase of more than 1.4 ng/mL within any 12-month period, or a total PSA above 4.0 ng/mL, should prompt urologic referral. Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has stated: "The saturation model suggests that prostate tissue is maximally stimulated at relatively low androgen concentrations, and raising testosterone from low-normal to mid-normal should not meaningfully increase prostate cancer risk" 10.

LUTS and BPH Overlap

Lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia are common in men over 50. While TRT does not appear to worsen LUTS in most controlled trials, the AACE 2020 position statement recommends baseline assessment with the International Prostate Symptom Score (IPSS) and follow-up scoring at 6 and 12 months 11. Men with severe baseline LUTS (IPSS ≥20) should ideally have their urinary symptoms optimized before Jatenzo initiation.

Bone Density: A Potential Benefit in This Age Group

Testosterone plays a direct role in bone metabolism through both androgen receptor activation and aromatization to estradiol. In men aged 50 to 64, age-related bone loss has typically begun but rarely progressed to osteoporosis unless other risk factors (glucocorticoid use, hypogonadism, low body weight) are present.

The Testosterone Trials (TTrials), a coordinated set of seven trials in 790 men aged 65 and older with low testosterone, found that 12 months of transdermal testosterone increased volumetric bone mineral density in the spine by 7.5% and in the hip by 3.2% compared to placebo, as measured by quantitative CT 12. While TTrials used gel rather than oral testosterone undecanoate, the bone effects are mediated by systemic testosterone levels, making the findings broadly applicable to Jatenzo-treated patients who achieve eugonadal ranges.

For men in the 50-to-64 bracket, this represents a meaningful secondary benefit of TRT. A DXA scan at baseline is reasonable if the patient has additional osteoporosis risk factors.

Dosing and Titration in Older Adults

Jatenzo uses a dose-titration protocol. The starting dose is 237 mg twice daily with food. Serum testosterone is checked after a minimum of 2 weeks, and the dose is adjusted in 79 mg increments (down to 158 mg or up to 396 mg, both twice daily) 9.

Meal Timing and Absorption

Lymphatic absorption requires dietary fat. Taking Jatenzo on an empty stomach reduces bioavailability substantially. The prescribing information specifies administration "with food," and the key trial required meals containing at least 30% fat 3. For older adults who eat smaller meals or follow low-fat diets (common in men managing cholesterol or weight), this requirement may need explicit counseling. A tablespoon of peanut butter or a small avocado portion is often enough.

Starting Low in High-Risk Patients

The Endocrine Society's 2018 guideline states: "In older men with hypogonadism who are considering testosterone therapy, we recommend that the clinician clearly discuss the uncertainty about risks and benefits" 2. For men with borderline hypertension, hematocrit above 50%, or multiple cardiovascular risk factors, some clinicians choose to start at 158 mg twice daily (one step below the standard starting dose) and titrate upward only after confirming stable blood pressure and hematocrit at 1 month. This approach is not in the label but reflects a conservative practice pattern supported by the guideline's risk-benefit framing.

When Jatenzo May Not Be Appropriate

Certain clinical scenarios in the 50-to-64 age group warrant caution or outright avoidance. Men with uncontrolled hypertension (systolic ≥160 mmHg), hematocrit above 50% at baseline, severe untreated sleep apnea, active or suspected prostate cancer, or New York Heart Association class III, IV heart failure should not start Jatenzo without addressing these conditions first 2 9. A baseline comprehensive metabolic panel, CBC with hematocrit, PSA, blood pressure, and lipid panel should be completed before the first prescription is written.